Blink Reminders and Meibomian Gland Loss in Digital Screen Users
Starting soon · Not applicable
Conditions studied: Dry Eye Syndromes, Meibomian Gland Dysfunction (Disorder)
In brief
This randomized clinical trial aims to evaluate if a blink reminder program ('BlinkEasy') reduces the progression of Meibomian gland loss in intensive digital screen users over three months , using infrared meibography as the primary structural measure. Additionally, the study will analyze changes in dry eye symptoms using the 12-item Ocular Surface Disease Index (OSDI) questionnaire and non-invasive tear break-up time (NIBUT).
Key facts
- Study ID
- NCT07430137
- Run by
- Asociación para Evitar la Ceguera en México
- People needed
- 28
- Starts
- 2026-02-19
- Expected to finish
- 2026-08-01
- Last updated by the study team
- 2026-02-27
Who can join
Age: 18 and older, up to 40. Sex: any. Healthy volunteers: not accepted.
You may qualify if…
- Participants aged 18 to 40 years.
- Intensive digital screen users, defined as an average screen time of ≥4 hours per day for at least 3 days per week.
- Ocular Surface Disease Index (OSDI) score ≥13 (indicating mild to severe symptoms).
- Non-invasive tear break-up time (NIBUT) ≤10 seconds measured by infrared meibography.
- Presence of visible Meibomian glands on baseline meibography, allowing for quantitative analysis.
- Technical ability to install and operate the BlinkEasy software on their primary digital device.
You may not qualify if…
- Active ocular disease, including infections, corneal ulcers, or acute conjunctivitis.
- History of ocular surgery (e.g., refractive surgery, cataract extraction) or significant ocular injury.
- Use of topical ophthalmic medications affecting the ocular surface (e.g., steroids, glaucoma medications, or cyclosporine) within the last 3 months.
- Active use of contact lenses that cannot be suspended for the duration of the 12-week study period.
- Systemic conditions known to affect the ocular surface (e.g., Sjögren's syndrome, Rheumatoid Arthritis).
- Diagnosis of Diabetes Mellitus (Type 1 or Type 2).
Full record on ClinicalTrials.gov
Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.